drugset
drugset / Trial / NCT05520372

Autologous Immune Enhancement Therapy (AIET) for Cancer Patients

NCT05520372 ↗

Phase 1 Completed 60 enrolled Vinmec Research Institute of Stem Cell and Gene Technology
NaSingle-groupOpen-labelTreatment

Summary

This is a retrospective study that included 60 cancer patients who underwent autologous NK cell and CD8 T cell therapy between January 2016 and December 2021

Timeline

Start
2016-01-01
Primary completion
2021-12-30
Completion
2021-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous immune enhancement therapy (AIET) Cell therapy — —

Indications

No indication recorded.